Two cases of myelofibrosis with severe thrombocytopenia and symptomatology successfully treated with combination of pomalidomide and ruxolitinib

Leukemia and Lymphoma

Volumn 56, Issue 2, 2015, Pages 524-526

  Andrei, Mirela ^a   Sindhu, Hemant ^a   Wang, Jen Chin ^a  

^a BROOKDALE UNIVERSITY HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; LENALIDOMIDE; POMALIDOMIDE; RUXOLITINIB; ANTINEOPLASTIC AGENT; PYRAZOLE DERIVATIVE; THALIDOMIDE;

ANEMIA; DISEASE SEVERITY; FATIGUE; HEART DISEASE; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; LETTER; LEUKOCYTE COUNT; MYELOFIBROSIS; MYELOPHTHISIC ANEMIA; PRIORITY JOURNAL; THROMBOCYTE; THROMBOCYTOPENIA; THROMBOSIS PREVENTION; TREATMENT OUTCOME; WEIGHT REDUCTION; AGED; ANALOGS AND DERIVATIVES; CASE REPORT; COMPLICATION; MALE; PATHOLOGY; PRIMARY MYELOFIBROSIS; QUALITY OF LIFE; THROMBOCYTE COUNT; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FATIGUE; HUMANS; LEUKOCYTE COUNT; MALE; PLATELET COUNT; PRIMARY MYELOFIBROSIS; PYRAZOLES; QUALITY OF LIFE; THALIDOMIDE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 84923930332     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.924121     Document Type: Letter

References (15)

1. Tefferi A, Vaidya R, Caramazza D, et al. Circulating interleukin (IL)-8, Il-2R, IL-12, and IL-15 are independently prognostic in primary myelofi brosis: a comprehensive cytokine profi ling study. J Clin Oncol 2011; 29: 1356-1363
2. Kroger N, Holler E, Kobbe G, et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelo fi brosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 2009; 114: 5264-5270
3. Verstovsek S, Mesa RA, Gotlieb J, et al. A double-blind, placebocontrolled trial of ruxolitinib for myelofi brosis. N Engl J Med 2012; 366: 799-807
4. H arrison C, Kiladjian J J, Al-Ali H K, et al. J AK inhibition with ruxolitinib versus best available therapy for myelofi brosis. N Engl J Med 2012; 366: 787-798
5. Mascarenhas J, Mughal TI, Verstovsek S. Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib. Curr Med Chem 2012; 19: 4399-4413
6. Teff eri A, Verstovsek S, Barosi G, et al. Pomalidomide is active in the treatment of anemia associated with myelofi brosis. J Clin Oncol 2009; 27: 4563-4569
7. Mesa RA, Schwager S, Radia D, et al. The myelofi brosis symptom assessment form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment to myelofi brosis. Leuk Res 2009; 33: 1199-1203
8. Teff eri A, Passamonti F, Barbui T, et al. Phase 3 study of pomalidomide in myeloproliferative neoplasm (MPN)-associated myelofi brosis with RBC-transfusion-dependence. Blood 2013; 122(Suppl. 1): Abstract 394
9. Begna KH, Pardanani A, Mesa R, et al. Long-term outcome of pomalidomide therapy in myelofi brosis. Am J Hematol 2012; 87: 66-68
10. Marchetti M, Barosi G, Balestri F, et al. Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofi brosis with myeloid metaplasia: a phase II trial. J Clin Oncol 2004; 22: 424-431
11. Mesa RA, Steensma DP, Pardanani A, et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofi brosis with myeloid metaplasia. Blood 2003; 101: 2534-2541
12. Weinkove R, Reilly JT, McMullin MF, et al. Low-dose thalidomide in myelofi brosis. Haematologic. 2008; 93: 1100-1101
13. Holle N, de Witte T, Mandigers C, et al. Th alidomide and lenalidomide in primary myelofi brosis. Neth J Med 2010; 68: 293-308
14. Th omas D A, Giles F J, Albitar M, et al. Th alidomide therapy for myelofi brosis with myeloid metaplasia. Cancer 2006; 106: 1974-1984
15. Daver N, Shastri A, Kadia T, et al. Modest activity of pomalidomide in patients with myelofi brosis and signifi cant anemia. Leuk Res 2013; 37: 1440-1444.